信迪利单抗治疗胃癌致1型糖尿病1例
A case of type 1 diabetes caused by gastric cancer treated with Sintilimab
高伊函 1陈婧姼 1付浩宇 1杨俊泉1
作者信息
- 1. 河北省唐山市人民医院放化一科,唐山 063001
- 折叠
摘要
免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)目前应用于多种肿瘤的治疗中,在肿瘤治疗中扮演着重要角色,随之而来的也有许多与免疫系统相关的不良反应.1型糖尿病(type diabetes mellitus.TIDM)是比较罕见的内分泌系统并发症,目前报道较少.我们报道1例使用ICIs治疗胃癌后出现T1DM的病例.患者男,34岁,使用信迪利单抗206 d后出现糖尿病酮症酸中毒,空腹血糖15.78mmol/L,糖化血红蛋白8.6％.胰岛相关抗体:谷氨酸脱羧酶抗体:119.2 kU/L;胰岛素抗体:＜2U/L.空腹胰岛素:0.21 mU/L;空腹C肽:0.12μg/L.通过对患者临床资料的分析,旨在提高临床医师对免疫相关性1型糖尿病的认识,同时为正确的诊治提供思路.
Abstract
Immune checkpoint inhibitors(ICIs)are currently used in the treatment of various tumors and play an important role in tumor treatment,resulting in many adverse reactions related to the immune system.Type 1 diabetes(T1DM)is a rare endocrine system complication,which is rarely reported at present.We report a case of T1DM after using ICIs to treat gastric cancer.The patient was a 34 year old male who developed diabetes ketoacidosis after 206 days of sintilimab monoclonal antibody use,with fasting blood glucose of 15.78 mmol/L and glycosylated hemoglobin of 8.6％.Islet related antibody:Glutamate decarboxylase antibody:119.2 IU/mL;Insulin antibody:＜2 IU/L.Fasting insulin:0.21 mU/L;Fasting C-peptide:0.12 μg/L.Through the analysis of patients'clinical data,it aims to improve clinicians'understanding of immune related type 1 diabetes and provide ideas for correct diagnosis and treatment.
关键词
胃肿瘤/免疫检查点抑制剂/免疫不良反应/1型糖尿病/信迪利单抗Key words
J Gastric tumors/Immune checkpoint inhibitors/Adverse immune reactions/Type 1 diabetes/Sintilimab引用本文复制引用
基金项目
吴阶平医学基金会临床科研专项资助基金(320.6750.19088-94)
出版年
2024
NETL
NSTL
万方数据